Mark Jaros

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Kausik K. Ray, R. Scott Wright, David Kallend et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Frederick J. Raal, David Kallend, Kausik K. Ray et al. · New England Journal of Medicine · 2020 · 755 citations · Full text

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mary E. Rinella, Manal F. Abdelmalek et al. · The Lancet · 2018 · 404 citations

Hepatology, Medicine, Liver Physiology +5

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

Stephen A. Harrison, Stephen J. Rossi, Angelo H. Paredes et al. · Hepatology · 2019 · 251 citations · Full text

Liver Fibrosis, Immunology, Gastroenterology +24

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

R. Scott Wright, Kausik K. Ray, Frederick J. Raal et al. · Journal of the American College of Cardiology · 2021 · 219 citations

Thrombosis, Familial Hypercholesterolemia, Cardiovascular Disease +9